CADTH | Evidence Driven
CADTH | Evidence Driven

Imbruvica for Waldenström’s Macroglobulinemia - Details

Details

Files
Generic Name:
Ibrutinib
Project Status:
Complete
Therapeutic Area:
Waldenstrom's Macroglobulinemia
Manufacturer:
Janssen Canada Inc.
Brand Name:
Imbruvica
Project Line:
Reimbursement Review
Project Number:
PC0082-000
NOC Status at Filing:
Post NOC
Strength:
140mg Capsules
Tumour Type:
Lymphoma
Indications:
Waldenstrom's Macroglobulinemia
Funding Request:
For the treatment of patients with Waldenström’s Macroglobulinemia who have received at least one prior therapy
Sponsor:
Janssen Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
Clarification:
Please note that the August pERC meeting was conducted over two days. The original target date for the posting of pERC Initial Recommendation remains as September 1, 2016.
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Ibrutinib (Imbruvica) for Waldenstrom's Macroglobulinemia – pERC Final Recommendation Final Recommendation November 3, 2016 View PDF
Ibrutinib (Imbruvica) for Waldenstrom's Macroglobulinemia – Final Clinical Guidance Report Guidance Reports November 3, 2016 View PDF
Ibrutinib (Imbruvica) for Waldenstrom's Macroglobulinemia – Final Economic Guidance Report Guidance Reports November 3, 2016 View PDF
Ibrutinib (Imbruvica) for Waldenstrom's Macroglobulinemia – pERC Initial Recommendation Initial Recommendation September 1, 2016 View PDF
Ibrutinib (Imbruvica) for Waldenstrom's Macroglobulinemia – PAG Feedback on Initial Recommendation Feedback November 3, 2016 View PDF
Ibrutinib (Imbruvica) for Waldenstrom's Macroglobulinemia – Manufacturer Feedback on Initial Recommendation Feedback November 3, 2016 View PDF
Ibrutinib (Imbruvica) for Waldenstrom's Macroglobulinemia – Patient Advocacy Group (CORD) Feedback on Initial Recommendation Feedback November 3, 2016 View PDF
Ibrutinib (Imbruvica) for Waldenstrom's Macroglobulinemia – Patient Advocacy Group (LC) Feedback on Initial Recommendation Feedback November 3, 2016 View PDF
Ibrutinib (Imbruvica) for Waldenstrom's Macroglobulinemia – Patient Advocacy Group(s) COI Declarations COI Declarations November 3, 2016 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : November 18, 2016